Skip to main content

Daily fosfomycin versus levofloxacin for complicated urinary tract infections.

Publication ,  Journal Article
Rouphael, N; Winokur, P; Keefer, MC; Traenkner, J; Drobeniuc, A; Doi, Y; Munsiff, S; Fowler, VG; Evans, S; Oler, RE; Tuyishimire, B; Lee, M ...
Published in: mBio
October 31, 2023

Concerns over resistance and safety have been identified in the current treatment regimen for complicated urinary tract infections. Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

mBio

DOI

EISSN

2150-7511

Publication Date

October 31, 2023

Volume

14

Issue

5

Start / End Page

e0167723

Location

United States

Related Subject Headings

  • Urinary Tract Infections
  • Levofloxacin
  • Humans
  • Fosfomycin
  • Cystitis
  • Anti-Bacterial Agents
  • 3207 Medical microbiology
  • 3107 Microbiology
  • 3101 Biochemistry and cell biology
  • 0605 Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rouphael, N., Winokur, P., Keefer, M. C., Traenkner, J., Drobeniuc, A., Doi, Y., … DMID 15-0045 study group, . (2023). Daily fosfomycin versus levofloxacin for complicated urinary tract infections. MBio, 14(5), e0167723. https://doi.org/10.1128/mbio.01677-23
Rouphael, Nadine, Patricia Winokur, Michael C. Keefer, Jessica Traenkner, Ana Drobeniuc, Yohei Doi, Sonal Munsiff, et al. “Daily fosfomycin versus levofloxacin for complicated urinary tract infections.MBio 14, no. 5 (October 31, 2023): e0167723. https://doi.org/10.1128/mbio.01677-23.
Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, et al. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. mBio. 2023 Oct 31;14(5):e0167723.
Rouphael, Nadine, et al. “Daily fosfomycin versus levofloxacin for complicated urinary tract infections.MBio, vol. 14, no. 5, Oct. 2023, p. e0167723. Pubmed, doi:10.1128/mbio.01677-23.
Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, Munsiff S, Fowler VG, Evans S, Oler RE, Tuyishimire B, Lee M, Ghazaryan V, Chambers HF, DMID 15-0045 study group. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. mBio. 2023 Oct 31;14(5):e0167723.

Published In

mBio

DOI

EISSN

2150-7511

Publication Date

October 31, 2023

Volume

14

Issue

5

Start / End Page

e0167723

Location

United States

Related Subject Headings

  • Urinary Tract Infections
  • Levofloxacin
  • Humans
  • Fosfomycin
  • Cystitis
  • Anti-Bacterial Agents
  • 3207 Medical microbiology
  • 3107 Microbiology
  • 3101 Biochemistry and cell biology
  • 0605 Microbiology